The Mission of the Institute is to improve the quality of life in the Wielkopolska and West Pomerania regions and nationwide by controlling cancer through
state-of-the-art ICT solutions leading to the development of new innovative methods of cancer diagnosis and treatment.
IIMO is a new scientific entity having the status of an Excellence Centre based in the Wielkopolska and West Pomerania regions
and part of the network of Europe's and world's leading oncology R&D centers.
The institute has been established by distinguished experts in experimental and clinical medicine and ICT
as a non-profit foundation meeting the requirements of a Public Benefit Organisation.
IIMO has a legal form of a non-profit foundation that fully meets the requirements of a research and knowledge-dissemination organisation
as defined by the Commission Regulation (EU) No. 651/2014 of 17 June 2014.
The Institute does not run any business activity as defined by the Act of 2 July 2004 on the freedom of economic activity.
IIMO founders have extensive experience in conducting translational biomedical studies and processing, analysing and collecting Big Data.
Furthermore, the founders have a substantial experience in the implementation of biomedical studies and ICT solutions to the economy.
Their achievements in scientific implementation include over 1,100 scientific publications in renowned international journals with over 22,000 quotes.
The founders have also developed tens of patents, many of which have been implemented to the Polish and global economy and established many businesses in the fields
of information and biomedical technologies aimed to commercialise their solutions.
The IIMO activities will be supervised by the Institute Scientific Board composed of distinguished experts in experimental and clinical oncology and ICT in Poland.
The IIMO is strategically guided by its International Scientific Committee, composed of distinguished international experts in experimental and clinical oncology and ICT.
Prof. Waldemar Priebe, professor of chemistry at MD Anderson Cancer Centre and innovator in the area of drug development in oncology,
serves as Chairmen of the ISC and is responsible for its activities.
The aim of the Committee is to set directions for the Institute’s research and development.